$ATXI
AVENUE THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000143774923031621 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.137M $1.160M $469.0K
YoY Change -66.23% 147.33% -21.04%
% of Gross Profit
Research & Development $982.0K $907.0K $194.0K
YoY Change 227.33% 367.53% -30.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.119M $907.0K $194.0K
YoY Change 606.33% 367.53% -30.22%
Operating Profit -$2.068M -$663.0K
YoY Change 211.92% -23.97%
Interest Expense $22.00K $10.00K $1.000K
YoY Change -99.5% 900.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $2.714M $2.581M $1.000K
YoY Change -51.36% 258000.0%
Pretax Income $617.0K $510.0K -$662.0K
YoY Change 17.75% -177.04% -24.0%
Income Tax
% Of Pretax Income
Net Earnings $640.0K $513.0K -$662.0K
YoY Change 11.3% -177.49% -24.0%
Net Earnings / Revenue
Basic Earnings Per Share $0.06 -$0.45
Diluted Earnings Per Share $0.03 $0.06 -$0.45
COMMON SHARES
Basic Shares Outstanding 13.25M 8.183M 22.13M
Diluted Shares Outstanding 8.200M 1.466M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.783M $160.0K $217.0K
YoY Change -73.42% -26.27% -62.91%
Cash & Equivalents $1.783M $161.0K $217.0K
Short-Term Investments
Other Short-Term Assets $67.00K $330.0K $358.0K
YoY Change -51.09% -7.82% 1134.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.850M $500.0K $575.0K
YoY Change -72.97% -13.04% -16.42%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $2.000K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.850M $500.0K $575.0K
Total Long-Term Assets $0.00 $2.000K $0.00
Total Assets $1.850M $502.0K $575.0K
YoY Change -72.97% -12.7% -16.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $78.00K $296.0K $364.0K
YoY Change -39.53% -18.68% 80.2%
Accrued Expenses $532.0K $1.430M $250.0K
YoY Change -15.96% 472.0% -61.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.196M $5.024M $614.0K
YoY Change -66.58% 718.24% -27.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.196M $5.024M $614.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.196M $5.024M $614.0K
YoY Change -66.58% 718.24% -27.59%
SHAREHOLDERS EQUITY
Retained Earnings -$90.90M -$91.60M -$81.10M
YoY Change 12.78% 12.95% 6.57%
Common Stock $3.000K $1.000K $81.09M
YoY Change -100.0% -100.0% 6.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.582M -$3.650M -$39.00K
YoY Change
Total Liabilities & Shareholders Equity $1.850M $502.0K $575.0K
YoY Change -72.97% -12.7% -16.42%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income $640.0K $513.0K -$662.0K
YoY Change 11.3% -177.49% -24.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.324M -$890.0K -$554.0K
YoY Change -44.26% 60.65% 3.36%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$1.000M
YoY Change
Cash From Investing Activities $0.00 -$1.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.946M 480.0K -119.0K
YoY Change -62.98% -503.36%
NET CHANGE
Cash From Operating Activities -2.324M -890.0K -554.0K
Cash From Investing Activities 0.000 -1.000M
Cash From Financing Activities 3.946M 480.0K -119.0K
Net Change In Cash 1.622M -1.410M -673.0K
YoY Change -75.01% 109.51% 25.56%
FREE CASH FLOW
Cash From Operating Activities -$2.324M -$890.0K -$554.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80551000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8964222
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8964222
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4773841
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4773841
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38114
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Kane Concourse, Suite 301
dei Entity Address City Or Town
EntityAddressCityOrTown
Bay Harbor Islands
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33154
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652‑4500
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ATXI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13247622
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6708000 usd
CY2023Q3 atxi Deferred Financing Costs
DeferredFinancingCosts
310000 usd
CY2022Q4 atxi Deferred Financing Costs
DeferredFinancingCosts
0 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
137000 usd
CY2023Q3 us-gaap Assets
Assets
502000 usd
CY2022Q4 us-gaap Assets
Assets
6845000 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3300000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2609000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5024000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3579000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
5024000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3579000 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87917000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84456000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91568000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3650000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3905000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-872000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-639000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4522000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
502000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6845000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
907000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
194000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5149000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2153000 usd
CY2023Q3 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
CY2022Q3 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
4230000 usd
atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1161000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
469000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3042000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1978000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2068000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-663000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12421000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4131000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
104000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 usd
CY2023Q3 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
CY2022Q3 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
332000 usd
atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2572000 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1544000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-0 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2581000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1316000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
513000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-662000 usd
us-gaap Profit Loss
ProfitLoss
-11105000 usd
us-gaap Profit Loss
ProfitLoss
-4127000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-88000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
526000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-662000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11017000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4127000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8114155
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1465691
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7155050
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1441542
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8200069
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1465691
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7155050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1441542
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6146000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
561000 usd
CY2023Q3 atxi Stock Issued During Period Value License Expense
StockIssuedDuringPeriodValueLicenseExpense
0 usd
CY2023Q3 atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
526000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4522000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 usd
atxi Stock And Prefunded Warrants Issued During Period Value Private Placement Net Of Issuance Costs
StockAndPrefundedWarrantsIssuedDuringPeriodValuePrivatePlacementNetOfIssuanceCosts
866000 usd
atxi Stock Issued During Period Value License Expense
StockIssuedDuringPeriodValueLicenseExpense
1230000 usd
atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
0 usd
atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-88000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11017000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4522000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
598000 usd
CY2022Q3 atxi Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-662000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-39000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3451000 usd
atxi Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
637000 usd
us-gaap Profit Loss
ProfitLoss
-4127000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-39000 usd
us-gaap Profit Loss
ProfitLoss
-11105000 usd
us-gaap Profit Loss
ProfitLoss
-4127000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
599000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
637000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1544000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
1230000 usd
atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
0 usd
atxi Research And Development License Acquried Expense
ResearchAndDevelopmentLicenseAcquriedExpense
3000000 usd
atxi Research And Development License Acquried Expense
ResearchAndDevelopmentLicenseAcquriedExpense
usd
atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
72000 usd
atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
0 usd
us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
13000 usd
us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
-90000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-119000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-87000 usd
atxi Increase Decrease In Deferred Financing Costs
IncreaseDecreaseInDeferredFinancingCosts
-239000 usd
atxi Increase Decrease In Deferred Financing Costs
IncreaseDecreaseInDeferredFinancingCosts
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7127000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3427000 usd
atxi Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
3000000 usd
atxi Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
atxi Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
3101000 usd
atxi Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
0 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
550000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
71000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
119000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3580000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-119000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6547000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3546000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6708000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3763000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
161000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
217000 usd
atxi Unpaid Deferred Financing Costs
UnpaidDeferredFinancingCosts
239000 usd
atxi Unpaid Deferred Financing Costs
UnpaidDeferredFinancingCosts
219000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company's consolidated financial statements include certain amounts that are based on management's best estimates and judgements. The Company's significant estimates include, but are <em style="font: inherit;">not</em> limited to, fair value of warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
413000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1460000 usd
CY2019Q4 atxi Contractual Obligation Development Expense
ContractualObligationDevelopmentExpense
81500000 usd
CY2019Q4 atxi Contractual Obligation Commercial Expense
ContractualObligationCommercialExpense
151000000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
296000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
129000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
230000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
199000 usd
CY2023Q3 atxi Accrued Contingent Fee
AccruedContingentFee
0 usd
CY2022Q4 atxi Accrued Contingent Fee
AccruedContingentFee
208000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
934000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
262500000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
949000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7877935
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29811
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1685000000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.14
atxi Sharebased Compensation Arrangement By Sharebased Payment Award Options Grands In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrandsInPeriodWeightedAverageRemainingContractualTerm
P10Y
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1685000000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1422500000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y8M12D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.249 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.257 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
98137
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.6
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
561000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
599000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
637000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4137916
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.3
CY2022 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1000 usd
CY2023Q1 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
3432598
CY2023Q1 atxi Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
0.88
CY2023Q1 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
400083
CY2023Q1 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7170431
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.32
CY2023Q1 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1272000 usd
CY2023Q2 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1092299
CY2023Q2 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6078132
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.55
CY2023Q2 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6078132
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.55
CY2023Q3 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1000 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
550000 usd

Files In Submission

Name View Source Status
atxi-20230930_cal.xml Edgar Link unprocessable
0001437749-23-031621-index-headers.html Edgar Link pending
0001437749-23-031621-index.html Edgar Link pending
0001437749-23-031621.txt Edgar Link pending
0001437749-23-031621-xbrl.zip Edgar Link pending
atxi-20230930.xsd Edgar Link pending
atxi20230930_10q.htm Edgar Link pending
ex_563737.htm Edgar Link pending
ex_563738.htm Edgar Link pending
ex_563739.htm Edgar Link pending
ex_563740.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
atxi-20230930_def.xml Edgar Link unprocessable
atxi-20230930_lab.xml Edgar Link unprocessable
atxi-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atxi20230930_10q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending